Tengion to Participate in Panel Discussion at ISSCR 11th Annual Meeting
WINSTON-SALEM, N.C., June 12, 2013
WINSTON-SALEM, N.C., June 12, 2013 /PRNewswire/ -- Tengion, Inc. (OTCQB:
TNGN), a leader in regenerative medicine, today announced that Dr. Tim
Bertram, the Company's President of Research and Development and Chief
Scientific Officer, will participate in a panel at the International Society
for Stem Cell Research (ISSCR) 11^th Annual Meeting being held June
12^th-15^th, 2013 in Boston, Massachusetts.
Dr. Bertram will take part in a panel discussion titled "Disease-focused
Research: From Bench to Bedside" on Thursday, June 13, 2013 at 11:30am to
12:30pm ET and will cover Tengion's groundbreaking research on the
regeneration of the kidney and hollow organs.
Tengion's platform applies cell-based technologies for tissue and organ
regeneration using a patient's own cells. The company's novel and proprietary
technology identifies these cells and uses them to create a neo-organ, with
the potential to develop new organs and tissues on a commercial scale.
Tengion has two clinical-stage products including the Neo-Urinary Conduit™
designed to establish a new standard of care for bladder cancer patients
undergoing cystectomy and the Neo-Kidney Augment™ intended to delay dialysis
and transplantation by increasing renal function in patients with advanced
chronic kidney disease.
ISSCR is the largest international interdisciplinary forum dedicated to stem
cell science. Shinya Yamanaka, M.D., Ph.D., the current president, was awarded
the Nobel Prize for Physiology or Medicine in 2012 for the discovery that
adult somatic cells can be reprogrammed to become pluripotent cells capable of
developing into all tissues of the body.
Tengion, a clinical-stage regenerative medicine company, is focused on
developing its Organ Regeneration Platform™ to harness the intrinsic
regenerative pathways of the body to regenerate a range of native-like organs
and tissues with the goal of delaying or eliminating the need for chronic
disease therapies, organ transplantation, and the administration of
anti-rejection medications. An initial clinical trial is ongoing for the
Company's most advanced product candidate, the Neo-Urinary Conduit™, an
autologous implant that is intended to catalyze regeneration of native-like
urinary tissue for bladder cancer patients requiring a urinary diversion
following bladder removal. The Company initiated a Phase 1 clinical trial in
Sweden in May 2013 for the Neo-Kidney Augment™, which is designed to prevent
or delay dialysis kidney transplantation by increasing renal function in
patients with advanced chronic kidney disease. Tengion has worldwide rights to
its product candidates.
SOURCE Tengion, Inc.
Contact: Investor and Media, Brian Davis, email@example.com,
Press spacebar to pause and continue. Press esc to stop.